Whitehawk
8 known investors
Find your way into Whitehawk
Sign up to see every warm intro you have to Whitehawk
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Whitehawk team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development. The company brings expertise in biotech R&D and commercialization to treat patients using its ADC platform.
Founders & leadership
DL

Dave Lennon, PhDPresident & CEO
DL

Dave LennonPresident & CEOPresident and CEO of Whitehawk Therapeutics, which develops antibody-drug conjugate therapeutics for treating patients.
Investors · 8
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · allsci.com · Not right? Tell us
InvusreportedNew York
How we know: allsci.com · Not right? Tell us
Also in the syndicate · 6
Acuta Capital PartnersADAR1 Capital ManagementCoastlands CapitalKVP CapitalQVTStemPoint Capital LP
Funding
SEC filings, press & company announcements- Undisclosed amountprivate placementMay 2026
Acuta Capital Partners, ADAR1 Capital Management, Avoro Capital, Coastlands Capital, Invus, KVP Capital, QVT, StemPoint Capital LP
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Whitehawk do?
- Whitehawk Therapeutics develops antibody-drug conjugate (ADC) therapeutics through intentional clinical development. The company brings expertise in biotech R&D and commercialization to treat patients using its ADC platform.
- Who are Whitehawk's investors?
- Whitehawk's investors include Avoro Capital Advisors, Invus.
